Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma in CheckMate 238.
Jeffrey S WeberMichele Del VecchioMario MandalaHelen J GogasAna M AranceStephane DalleC Lance CoweyMichael SchenkerJean-Jacques GrobVanna Chiarion SileniIvan Marquez-RodasMarcus O ButlerAnna Maria Di GiacomoLuis de la Cruz MerinoPetr ArenbergerVictoria AtkinsonAndrew HillLeslie A FecherMichael MillwardNikhil I KhushalaniPaola QueiroloGeorgina V LongMaurice LoboMargarita AskelsonPaolo Antonio AsciertoJames M G LarkinPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Postrecurrence survival was longer for patients who recurred >12 months. Patients on nivolumab who recurred early benefitted from SST but had better survival with ipilimumab-based regimens or targeted therapy compared with anti-PD-1 monotherapy.
Keyphrases
- end stage renal disease
- prognostic factors
- chronic kidney disease
- ejection fraction
- newly diagnosed
- dna damage
- peritoneal dialysis
- early stage
- combination therapy
- lymph node
- free survival
- cell cycle
- stem cells
- clinical trial
- adipose tissue
- randomized controlled trial
- patient reported outcomes
- cell therapy
- study protocol
- insulin resistance
- glycemic control